COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Search Clinical Trials

Clinical Trials Category

Reset

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

12 results for "Cancer" and "Endocrine Cancers" and "Colorectal"

High Dose Re-Irradiation Utilizing Advanced Defromable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)

A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Sub Category
Brain and Spine Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers, Breast Cancers

A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors

Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
Protocol No
TOLERO-TP-1287-101
Sub Category
Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers

A Phase 1 Trial of Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine therapy in HR+/Her 2- Advanced Breast Cancer after a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors

A Phase 1 Trial of Hydroxychloroquine (HCQ) in Combination with Abemaciclib and Endocrine Therapy in HR+/Her 2- Advanced Breast Cancer after a Lead in Dose Escalation Cohort of HCQ and Abemaciclib in Advanced Solid Tumors
Protocol No
IIT-MENON-COINCIDE
Sub Category
Breast Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Prostate and Urologic Cancers, Head and Neck Cancers, Gynecologic Cancers, Gastrointestinal Cancers, Endocrine Cancers

A Phase I Study of GNX102 in Patients with Advanced Solid Tumors

This new medicine, GNX102, is an antibody that binds to a certain target on the surface of the cancer cells and may kill the cancer cells.

The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.
Protocol No
GLYCONEX-GNX-001
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Skin Cancers, Prostate and Urologic Cancers, Gynecologic Cancers

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility
Protocol No
ADP-0000-001-SCR
Sub Category
Gynecologic Cancers, Prostate and Urologic Cancers, Thoracic Cancers, Sarcoma, Skin Cancers, Head and Neck Cancers, Gastrointestinal Cancers

An Open-Label, Multiple-Dose, Dose- Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma

This is a Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Protocol No
VMONCOLOGY-VMO-01C
Sub Category
Early Phase/Multiple Disease Site Cancers, Thoracic Cancers, Head and Neck Cancers, Gynecologic Cancers